Is pain part of a systemic syndrome in head and neck cancer?
Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about 180,000 cancer deaths per year. Patients with HNC are characterized by a systemic inflammatory state, generally associated with worse outcomes. Treatment-related toxicity is common among HNC patients and causes systemic consequences such as fatigue or cognitive dysfunction. The therapeutic treatments of HNC involve the release in circulation of inflammatory systemic mediators, whose effects trigger a vicious circle that may lead to functional and behavioral alterations. The areas of the head and neck are highly sensitive to pain. Literature data confirm that in HNC patients, pain is one of the most distressing symptoms across all the phases of treatment. Pain is associated with worse general conditions, depression, fatigue, impaired cognitive functions, and lower survival rate. The treatment of advanced HNC cases is multimodal and requires a multidisciplinary psycho-socio-pharmacological approach mediated by a team of experts. The pharmacological approach in management of HNC patients with pain is fundamental and involves the use of opioids, NSAIDs, steroids, or other drugs. Opioids in pain management therapy in patients with HNC could allow the pain level to be adequately monitored, thus improving quality of life. The integration of opioid and non-opioid therapy as well as non-pharmacological interventions is essential for the rehabilitation of physical, social, and psychological functions and to achieve pain control in patients with HNC. Opioid treatment is the mainstay for pain control, being used both for background and breakthrough cancer pain (BTcP) episodes. Fentanyl, easily absorbed and generally well tolerated, appears to be a possible choice due to its versatility. Non-pharmacological interventions, such as tailored yoga, physical exercise, and acupuncture, may have a role in pain management in patients with HNC.
KeywordsHead and neck cancer Pain Pain management Multidisciplinary approach Opioids
The authors acknowledge Annarita Chieti, PhD, of Sanitanova S.r.l., who is responsible for the medical writing and editorial assistance.
Compliance with ethical standards
Conflict of interest
Paolo Bossi is a part of advisory boards of/consultant for Angelini, Roche, Merck, Kyowa Kirin, Astrazeneca, MSD, BMS, SunPharma, and Sanofi. Other authors have nothing to declare.
- 17.Howren MB, Christensen AJ, Karnell LH ynd., Funk GF. Psychological factors associated with head and neck cancer treatment and survivorship: evidence and opportunities for behavioral medicine. J Consult Clin Psychol. 2013. doi: https://doi.org/10.1037/a0029940 PubMedCrossRefPubMedCentralGoogle Scholar
- 18.Pendergrass JC, Targum SD, Harrison JE (2018) Cognitive impairment associated with cancer: a brief review. Innov Clin Neurosci.Google Scholar
- 23.Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999) Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. https://doi.org/10.1523/JNEUROSCI.19-12-05034.1999 PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Xiao C, Hanlon A, Zhang Q et al (2013) Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2012.10.004 PubMedCrossRefGoogle Scholar
- 40.Logan RM, Gibson RJ, Sonis ST, Keefe DMK (2007) Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2006.04.011 PubMedCrossRefPubMedCentralGoogle Scholar
- 44.Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J (1992) Circulating cytokines: the tip of the iceberg? Circ ShockGoogle Scholar
- 46.Mejias NH, Martinez CC, Stephens ME, De Rivero Vaccari JP (2018) Contribution of the inflammasome to inflammaging. J Inflamm (United Kingdom). https://doi.org/10.1186/s12950-018-0198-3
- 50.Allen A, Flynn J, Mahadevan A et al (2009) Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 115(19):4514–4523. https://doi.org/10.1002/cncr.24525 CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Clarkson JE, Worthington HV, Furness S, McCabe M, MS KT, Hv W, Furness S, Mccabe M, Khalid T, Meyer S (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment ( Review ). Cochrane Libr. (8). https://doi.org/10.1002/14651858.CD001973.pub4
- 55.Allison RR, Ambrad AA, Arshoun Y et al (2014) Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. https://doi.org/10.1002/cncr.28553 PubMedPubMedCentralCrossRefGoogle Scholar
- 60.Bell BC, Butler EB (2013) Management of predictable pain using fentanyl pectin nasal spray in patients undergoing radiotherapy. J Pain Res. https://doi.org/10.2147/JPR.S54788
- 63.Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D (1997) Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain. https://doi.org/10.1016/S0304-3959(96)03254-X PubMedCrossRefGoogle Scholar
- 64.Bossi P, Locati L, Bergamini C et al (2014) Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2014.06.013 PubMedCrossRefGoogle Scholar
- 67.Zeppetella G, Davies AN (2015) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004311.pub4
- 69.Hanna B, Cohen E, Leach S, Boyd S, Botti M, Robbins J (2009) Pain beliefs and pain management of oncology patients. Cancer Nurs. 31(2):E1–E8. https://doi.org/10.1097/01.ncc.0000305693.67131.7d CrossRefGoogle Scholar
- 70.Enting RH, Oldenmenger WH, Van Gool AR, van der Rijt CCD, Sillevis Smitt PAE (2007) The effects of analgesic prescription and patient adherence on pain in a dutch outpatient cancer population. J Pain Symptom Manage. https://doi.org/10.1016/j.jpainsymman.2007.01.007 PubMedCrossRefPubMedCentralGoogle Scholar
- 71.Lalla RV, Choquette LE, Curley KF et al (2014) Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2014.08.001 PubMedPubMedCentralCrossRefGoogle Scholar
- 73.Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ, Moore M (2009) Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007076.pub2
- 77.Mustian KM (2013) Yoga as treatment for insomnia among cancer patients and survivors: a systematic review. Eur Med journal Oncol.Google Scholar
- 80.van Nieuwenhuizen AJ, Buffart LM, van Uden-Kraan CF et al (2018) Patient-reported physical activity and the association with health-related quality of life in head and neck cancer survivors. Support Care Cancer. 26:1087–1095. https://doi.org/10.1007/s00520-017-3926-y CrossRefPubMedPubMedCentralGoogle Scholar